ConductScience.org, home

Paper20046568

Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies.

Lynch CM and 2 others. MAbs, 2009. Cited by 31 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies. Papers, record 20046568. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20046568

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies.
PubMed
Journal
MAbs
PubMed
Year
2009
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
31
iCite
Relative citation ratio, by iCite
0.83
iCite
Revised in PubMed
2025-05-20
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lynch CMCarmel M
2Hart BWBruce W
3Grewal ISIqbal S

Source PubMed

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Guidelines as TopicMajor topic
Animals
Drug Evaluation, Preclinical
Humans
Recombinant Proteins

Source PubMed

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118,363,992Engineering therapeutic monoclonal antibodies.Immunol Rev2008https://conductscience.org/library/papers/18363992PubMed
229,451,320Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.Br J Clin Pharmacol2018https://conductscience.org/library/papers/29451320PubMed
316,107,258An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen.J Immunol Methods2005https://conductscience.org/library/papers/16107258PubMed
412,826,605Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.Proc Natl Acad Sci U S A2003https://conductscience.org/library/papers/12826605PubMed
516,299,896Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies.Clin Chem2005https://conductscience.org/library/papers/16299896PubMed
612,509,759Therapeutic antibodies for human diseases at the dawn of the twenty-first century.Nat Rev Drug Discov2003https://conductscience.org/library/papers/12509759PubMed
79,676,753Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial.J Rheumatol1998https://conductscience.org/library/papers/9676753PubMed
810,734,150Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4.J Pharmacol Exp Ther2000https://conductscience.org/library/papers/10734150PubMed
910,692,049Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4-specific monoclonal antibodies: CD4+ T-cell depletion is not required.Immunology2000https://conductscience.org/library/papers/10692049PubMed
1015,230,298Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients.Lupus2004https://conductscience.org/library/papers/15230298PubMed
118,638,281Immunotoxicity assessment of biotechnology products: a regulatory point of view.Toxicology1995https://conductscience.org/library/papers/8638281PubMed
1216,822,577Antibody production.Adv Drug Deliv Rev2006https://conductscience.org/library/papers/16822577PubMed
1316,908,486Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.N Engl J Med2006https://conductscience.org/library/papers/16908486PubMed
1416,622,479Potent antibody therapeutics by design.Nat Rev Immunol2006https://conductscience.org/library/papers/16622479PubMed
1517,592,672Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.Clin Breast Cancer2007https://conductscience.org/library/papers/17592672PubMed
1618,690,886The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.Curr Clin Pharmacol2008https://conductscience.org/library/papers/18690886PubMed
1717,038,473Natalizumab and progressive multifocal leucoencephalopathy.Ann Rheum Dis2006https://conductscience.org/library/papers/17038473PubMed
1815,122,047Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges.Mol Biotechnol2004https://conductscience.org/library/papers/15122047PubMed
1916,151,394Monoclonal antibody successes in the clinic.Nat Biotechnol2005https://conductscience.org/library/papers/16151394PubMed
2015,947,082Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.N Engl J Med2005https://conductscience.org/library/papers/15947082PubMed

See all 39 references

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.

PMIDTitleJournalYearIn PapersSource
42,610,927Overcoming Electrochemiluminescence Immunoassay (ECLIA) Limitations: Conformation-Independent Quantitation of a Therapeutic Antibody by LC-MS/MS.Anal Chem2026https://conductscience.org/library/papers/42610927PubMed
41,772,369QT Prolongation Risk of Antibody-Drug Conjugates.Drug Saf2026https://conductscience.org/library/papers/41772369PubMed
39,952,240Ligand-induced assembly of antibody variable fragments for the chemical regulation of biological processes.Cell Chem Biol2025https://conductscience.org/library/papers/39952240PubMed
38,348,660Immunocapture LC-MS methods for pharmacokinetics of large molecule drugs.Bioanalysis2024https://conductscience.org/library/papers/38348660PubMed
37,686,240Corneal Wound Healing in the Presence of Antifibrotic Antibody Targeting Collagen Fibrillogenesis: A Pilot Study.Int J Mol Sci2023https://conductscience.org/library/papers/37686240PubMed
34,445,651The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies.Int J Mol Sci2021https://conductscience.org/library/papers/34445651PubMed
31,776,588Correlation between antidrug antibodies, pre-existing antidrug reactivity, and immunogenetics (MHC class II alleles) in cynomolgus macaque.Immunogenetics2019https://conductscience.org/library/papers/31776588PubMed
31,502,016Editorial: A Novel Monoclonal Antibody-Targeting Angiogenesis by Inhibiting Secreted Frizzled-Related Protein 2.Ann Surg Oncol2019https://conductscience.org/library/papers/31502016PubMed
30,469,350Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies.Int J Mol Sci2018https://conductscience.org/library/papers/30469350PubMed
30,320,117Regulatory Pathway for Licensing Biotherapeutics in Mexico.Front Med (Lausanne)2018https://conductscience.org/library/papers/30320117PubMed
30,021,009Preclinical toxicological assessment of a novel monoclonal antibody targeting human platelet-derived growth factor CC (PDGF-CC) in PDGF-CChum mice.PLoS One2018https://conductscience.org/library/papers/30021009PubMed
28,154,831Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.J Immunol Res2017https://conductscience.org/library/papers/28154831PubMed
25,681,157The development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment.Curr Pain Headache Rep2015https://conductscience.org/library/papers/25681157PubMed
23,774,668Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgG.MAbs2013https://conductscience.org/library/papers/23774668PubMed
21,966,461A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity.PLoS One2011https://conductscience.org/library/papers/21966461PubMed
21,822,050Bridging the gap: facilities and technologies for development of early stage therapeutic mAb candidates.MAbs2011https://conductscience.org/library/papers/21822050PubMed
21,079,042Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.Pharmacol Rev2010https://conductscience.org/library/papers/21079042PubMed
20,421,713Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies.MAbs2010https://conductscience.org/library/papers/20421713PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20046568

GET https://conductscience.org/api/papers/v1/20046568/references?page=2